BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv 2020;4:2192-201. [PMID: 32433746 DOI: 10.1182/bloodadvances.2020001779] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 41.0] [Reference Citation Analysis]
Number Citing Articles
1 Neuendorff NR, Gagelmann N, Singhal S, Meckstroth S, Thibaud V, Zhao Y, Mir N, Shih Y, Amaro DM, Roy M, Lombardo J, Gjærde LK, Loh KP. Hypomethylating agent-based therapies in older adults with acute myeloid leukemia – A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee. Journal of Geriatric Oncology 2022. [DOI: 10.1016/j.jgo.2022.11.005] [Reference Citation Analysis]
2 Cooperrider JH, Shukla N, Nawas MT, Patel AA. The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia. JCO Oncology Practice 2022. [DOI: 10.1200/op.22.00342] [Reference Citation Analysis]
3 Huerga-domínguez S, Villar S, Prósper F, Alfonso-piérola A. Updates on the Management of Acute Myeloid Leukemia. Cancers 2022;14:4756. [DOI: 10.3390/cancers14194756] [Reference Citation Analysis]
4 Xu H, Wen Y, Jin R, Chen H. Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia. Front Pediatr 2022;10:975819. [DOI: 10.3389/fped.2022.975819] [Reference Citation Analysis]
5 Maurillo L, Spagnoli A, Candoni A, Papayannidis C, Borlenghi E, Lazzarotto D, Fianchi L, Sciumè MR, Zannier ME, Buccisano F, Principe MID, Mancini V, Breccia M, Fanin R, Todisco E, Lunghi M, Palmieri R, Fracchiolla N, Musto P, Rossi G, Venditti A. Comparison between azacitidine and decitabine as front-line therapy in elderly treatment naïve Acute Myeloid Leukemia not eligible for intensive chemotherapy.. [DOI: 10.21203/rs.3.rs-1926915/v1] [Reference Citation Analysis]
6 Dennis M, Copland M, Kaur H, Kell J, Nikolousis E, Mehta P, Palanicawandar R, Potter V, Raj K, Thomas I, Wilson A. Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper. Br J Haematol 2022. [PMID: 36000944 DOI: 10.1111/bjh.18369] [Reference Citation Analysis]
7 Chen Y, Cao J, Ye Y, Luo L, Zheng X, Yang X, Zheng Z, Zheng J, Yang T, Hu J. Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience. J Chemother 2022;:1-8. [PMID: 35881409 DOI: 10.1080/1120009X.2022.2097433] [Reference Citation Analysis]
8 Serroukh Y, Hébert J, Busque L, Mercier F, Rudd CE, Assouline S, Lachance S, Delisle J. Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100991] [Reference Citation Analysis]
9 Raslan O, Garcia-Horton A. Azacitidine and its role in the upfront treatment of acute myeloid leukemia. Expert Opin Pharmacother 2022;23:873-84. [PMID: 35695017 DOI: 10.1080/14656566.2022.2082284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia? Cancers 2022;14:2434. [DOI: 10.3390/cancers14102434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Labrador J, Martínez-Cuadrón D, de la Fuente A, Rodríguez-Veiga R, Serrano J, Tormo M, Rodriguez-Arboli E, Ramos F, Bernal T, López-Pavía M, Trigo F, Martínez-Sánchez MP, Rodríguez-Gutiérrez JI, Rodríguez-Medina C, Gil C, Belmonte DG, Vives S, Foncillas MÁ, Pérez-Encinas M, Novo A, Recio I, Rodríguez-Macías G, Bergua JM, Noriega V, Lavilla E, Roldán-Pérez A, Sanz MA, Montesinos P, On Behalf Of Pethema Group. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. Cancers (Basel) 2022;14:2342. [PMID: 35565471 DOI: 10.3390/cancers14092342] [Reference Citation Analysis]
12 Santini V, Lübbert M, Wierzbowska A, Ossenkoppele GJ. The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia. Adv Ther 2022;39:1474-88. [PMID: 34786648 DOI: 10.1007/s12325-021-01948-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Andreozzi F, Massaro F, Wittnebel S, Spilleboudt C, Lewalle P, Salaroli A. New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy. Int J Mol Sci 2022;23:3887. [PMID: 35409248 DOI: 10.3390/ijms23073887] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Huntington SF, Ingham MP, Okonkwo L, Singh A, Wang R, Ammann EM. Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020. Leuk Lymphoma 2021;:1-11. [PMID: 34913805 DOI: 10.1080/10428194.2021.2012666] [Reference Citation Analysis]
15 Marchetti M, Albertin L, Limberti G, Canicattì M. Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy. Expert Opin Pharmacother 2021;:1-10. [PMID: 34886738 DOI: 10.1080/14656566.2021.2014453] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Thol F. What to use to treat AML: the role of emerging therapies. Hematology Am Soc Hematol Educ Program 2021;2021:16-23. [PMID: 34889359 DOI: 10.1182/hematology.2021000309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
17 Shallis RM, Stahl M, Bewersdorf JP, Zeidan AM. The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia. Hemato 2021;2:748-763. [DOI: 10.3390/hemato2040051] [Reference Citation Analysis]
18 Makowka P, Stolp V, Stoschek K, Serve H. Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia. Biol Chem 2021;402:1547-64. [PMID: 34700366 DOI: 10.1515/hsz-2021-0288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Bewersdorf JP, Patel KK, Huntington SF, Zeidan AM. Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. Blood Adv 2021;5:4686-90. [PMID: 34525174 DOI: 10.1182/bloodadvances.2021005472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Saiz-Rodríguez M, Labrador J, Cuevas B, Martínez-Cuadrón D, Campuzano V, Alcaraz R, Cano I, Sanz MA, Montesinos P. Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:5677. [PMID: 34830832 DOI: 10.3390/cancers13225677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Liesveld JL, Baran A, Azadniv M, Misch H, Nedrow K, Becker M, Loh KP, O'Dwyer KM, Mendler JH. A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia. Leuk Res 2021;112:106749. [PMID: 34839054 DOI: 10.1016/j.leukres.2021.106749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhao G, Wang Q, Li S, Wang X. Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism. Front Oncol 2021;11:706030. [PMID: 34650913 DOI: 10.3389/fonc.2021.706030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Urbino I, Secreto C, Olivi M, Apolito V, D'Ardia S, Frairia C, Giai V, Aydin S, Freilone R, Dellacasa C, Giaccone L, Ferrero D, Audisio E, Busca A, Cerrano M. Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021. Cancers (Basel) 2021;13:5075. [PMID: 34680226 DOI: 10.3390/cancers13205075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Hindley A, Catherwood MA, McMullin MF, Mills KI. Significance of NPM1 Gene Mutations in AML. Int J Mol Sci 2021;22:10040. [PMID: 34576201 DOI: 10.3390/ijms221810040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Shallis RM, Podoltsev NA. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. Curr Opin Hematol 2021;28:110-21. [PMID: 33394722 DOI: 10.1097/MOH.0000000000000637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Rungjirajittranon T, Kungwankiattichai S, Kunacheewa C, Owattanapanich W. The Real-Life Efficacy of Fixed-Dose Hypomethylating Agents in Older Patients With Acute Myeloid Leukemia: A 10-Year Experience. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00279-2. [PMID: 34364821 DOI: 10.1016/j.clml.2021.07.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Thol F, Heuser M. Treatment for Relapsed/Refractory Acute Myeloid Leukemia. Hemasphere 2021;5:e572. [PMID: 34095756 DOI: 10.1097/HS9.0000000000000572] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
28 Patel AA, Cahill K, Saygin C, Odenike O. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv 2021;5:2264-71. [PMID: 33904891 DOI: 10.1182/bloodadvances.2020002929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
29 Patel KK, Zeidan AM, Shallis RM, Prebet T, Podoltsev N, Huntington SF. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv 2021;5:994-1002. [PMID: 33591323 DOI: 10.1182/bloodadvances.2020003902] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
30 Wang CY, Huang HH, Chen HM, Hsiao FY, Ko BS. Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015. Clin Lymphoma Myeloma Leuk 2021;21:e649-57. [PMID: 33931380 DOI: 10.1016/j.clml.2021.03.010] [Reference Citation Analysis]
31 Halpern AB, Walter RB. Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings. Hematology Am Soc Hematol Educ Program 2020;2020:129-34. [PMID: 33275691 DOI: 10.1182/hematology.2020000097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
32 Sarkaria SM, Heaney ML. Glasdegib in newly diagnosed acute myeloid leukemia. Expert Rev Anticancer Ther 2021;21:573-81. [PMID: 33593233 DOI: 10.1080/14737140.2021.1891885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Jeurkar C, Wilde L, Leiby BE, Banks J, Kasner M, Keiffer G, Filicko-O'Hara J, Palmisiano N. Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival. Leuk Res 2021;103:106533. [PMID: 33621825 DOI: 10.1016/j.leukres.2021.106533] [Reference Citation Analysis]
34 Agarwal S, Kowalski A, Schiffer M, Zhao J, Bewersdorf JP, Zeidan AM. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer? Expert Rev Hematol 2021;14:199-210. [PMID: 33459064 DOI: 10.1080/17474086.2021.1876559] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol 2021;39:1584-94. [PMID: 33449813 DOI: 10.1200/JCO.20.02341] [Cited by in Crossref: 125] [Cited by in F6Publishing: 140] [Article Influence: 125.0] [Reference Citation Analysis]
36 Conneely SE, Stevens AM. Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy. Curr Oncol Rep 2021;23:16. [PMID: 33439382 DOI: 10.1007/s11912-020-01009-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
37 Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, Begna K, Elliott M, Hogan W, Litzow M, Shah M, Pardanani A, Patnaik M, Tefferi A, Gangat N. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol 2020;95:1511-21. [PMID: 32833294 DOI: 10.1002/ajh.25978] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
38 Bewersdorf JP, Zeidan AM. Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? Best Pract Res Clin Haematol 2020;33:101222. [PMID: 33279182 DOI: 10.1016/j.beha.2020.101222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
39 Huang HH, Hsiao FY, Chen HM, Wang CY, Ko BS. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study. Br J Haematol 2021;192:110-8. [PMID: 33131074 DOI: 10.1111/bjh.17142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]